×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CMND – clearmind medicine inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CMND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/26
06:59 am
cmnd
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Medium
Report
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
12/24
07:14 am
cmnd
Clearmind Medicine receives IRB approval for Phase I/IIa clinical trial of CMND-100 [Seeking Alpha]
High
Report
Clearmind Medicine receives IRB approval for Phase I/IIa clinical trial of CMND-100 [Seeking Alpha]
12/24
06:59 am
cmnd
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial [Yahoo! Finance]
High
Report
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial [Yahoo! Finance]
12/24
06:55 am
cmnd
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
High
Report
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
12/16
08:37 am
cmnd
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
High
Report
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
10/10
08:15 am
cmnd
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site [Yahoo! Finance]
Medium
Report
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site [Yahoo! Finance]
10/10
08:07 am
cmnd
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
Low
Report
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/26
08:07 am
cmnd
Form 6-K Clearmind Medicine Inc. For: Dec 26
Low
Report
Form 6-K Clearmind Medicine Inc. For: Dec 26
12/9
05:12 pm
cmnd
Form S-8 Clearmind Medicine Inc.
Low
Report
Form S-8 Clearmind Medicine Inc.
12/6
05:01 pm
cmnd
Form 6-K Clearmind Medicine Inc. For: Dec 06
Medium
Report
Form 6-K Clearmind Medicine Inc. For: Dec 06
11/20
04:01 pm
cmnd
Form 6-K Clearmind Medicine Inc. For: Nov 20
Low
Report
Form 6-K Clearmind Medicine Inc. For: Nov 20
11/14
05:09 pm
cmnd
Form SC 13G/A Clearmind Medicine Inc. Filed by: Iroquois Capital Management, LLC
Medium
Report
Form SC 13G/A Clearmind Medicine Inc. Filed by: Iroquois Capital Management, LLC
10/10
04:01 pm
cmnd
Form 6-K Clearmind Medicine Inc. For: Oct 10
Medium
Report
Form 6-K Clearmind Medicine Inc. For: Oct 10
10/1
06:04 am
cmnd
Form EFFECT Clearmind Medicine Inc.
Low
Report
Form EFFECT Clearmind Medicine Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: